32,694 Results

Pivotal phase III data of Bavencio + Inlyta for renal cell carcinoma is published in NEJM.- Merck KGaA + Pfizer

 Added 1 day ago

Merck KGaA and Pfizer Inc. announced the publication of results from an interim analysis of the pivotal JAVELIN Renal 101...

Darolutamide + ADT extends metastasis-free survival in non-metastatic castration-resistant prostate cancer. Bayer HealthCare

 Added 2 days ago

Results from the pivotal Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a statistically significant...

Bayer acquires global rights to Vitrakvi and Loxo 195.

 Added 2 days ago

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive...

Genentech completes sBLA for Kadcyla for adjuvant treatment of HER2-positive early breast cancer (EBC) with residual disease.

 Added 2 days ago

Genentech, a member of the Roche Group announced completing the submission of a supplemental Biologics License Application to the FDA...

FDA postpones PDUFA decision for Duobrii a proposed treatment for psoriasis.- Ortho Dermatologics

 Added 2 days ago

Bausch Health Companies Inc.and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced that...

J&J via Ethicon acquires Auris Medical and its robotic technologies

 Added 3 days ago

Johnson & Johnson announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4...

CE Mark for Ascyrus Medical Dissection Stent-Ascyrus Medical

 Added 3 days ago

Ascyrus Medical, a privately-owned medical device company focused on innovative treatments for aortic dissections, announced the CE mark approval of...

Opdivo + Yervoy success in CheckMate 650 trial for prostate cancer. -BMS

 Added 3 days ago

Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer...

Keytruda and Lynparza early findings for treatment of prostate cancer.- Merck Inc.

 Added 4 days ago

Merck Inc., announced the presentation of interim data from the Phase 1b/II KEYNOTE-365 umbrella trial investigating Keytruda, Merck’s anti-PD-1 therapy,...

Phase III study of Crysvita demonstrates superiority in X-linked hypophosphatemia.- Ultragenyx Pharma + Kyowa Hakko Kirin

 Added 4 days ago

Ultragenyx Pharmaceutical, Kyowa Hakko Kirin, and Kyowa Kirin International announced positive results of a 64-week efficacy and safety analysis of...

Load more